SCHEMBL9892655

SCHEMBL9892655

O=C(O)Cc1cc(C(F)(F)F)ccc1-c1cccc(F)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGDR2 Q9Y5Y4 6/20 0.47
PSEN1 P49768 1/20 0.47
PSEN2 P49810 1/20 0.47
APH1B Q8WW43 1/20 0.47
NCSTN Q92542 1/20 0.47
APH1A Q96BI3 1/20 0.47
PSENEN Q9NZ42 1/20 0.47
RXRA P19793 5/20 0.46
RXRB P28702 3/20 0.46
RXRG P48443 3/20 0.46
KDM4E B2RXH2 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
PPARG P37231 1/20 0.44
AKR1C3 P42330 2/20 0.43
AKR1C2 P52895 2/20 0.43
IDH2 P48735 1/20 0.43
GCGR P47871 1/20 0.43
TBXA2R P21731 1/20 0.42
PTGDR Q13258 1/20 0.42
PTPN1 P18031 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9892663 0.89 GCGR (0.49) PTGDR2PSEN1PSEN2APH1BNCSTN
SCHEMBL9892692 0.88 ICMT (0.53) PTGDR2AKR1C3AKR1C2IDH2PTPN1
SCHEMBL9892653 0.87 PSEN1 (0.56) PTGDR2PSEN1PSEN2APH1BNCSTN
SCHEMBL9890671 0.86 PTGDR2 (0.50) PTGDR2KDM4ESMN1; SMN2PPARGTBXA2R
SCHEMBL9890672 0.82 PSEN1 (0.61) PTGDR2PSEN1PSEN2APH1BNCSTN
SCHEMBL9890674 0.81 SUCNR1 (0.46) PTGDR2KDM4ESMN1; SMN2PPARGAKR1C3
SCHEMBL9890677 0.81 PTGS2 (0.47) PTGDR2KDM4ESMN1; SMN2PPARGTBXA2R
SCHEMBL9105295 0.80 PTGER1 (0.57) PTGDR2KDM4ESMN1; SMN2TBXA2RPTGDR
SCHEMBL9890640 0.79 PTGER1 (0.53) PTGDR2RXRARXRBRXRGAKR1C3
SCHEMBL593792 0.79 ALOX5AP (0.53) KDM4EAKR1C3AKR1C2IDH2PTPN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120142771-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2012-06-07 US disclosed
EP-2374790-A1 BIPHENYLACETAMIDE DERIVATIVE Dainippon Sumitomo Pharma Co., Ltd. (JP) 2011-10-12 EP disclosed
US-20110224304-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2011-09-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120142771-A1 BIPHENYLACETAMIDE DERIVATIVE HRH3, KCNH3, BRPF3 PTGDR2 1062/4885PSEN1 2126/4885PSEN2 1867/4885
US-20110224304-A1 BIPHENYLACETAMIDE DERIVATIVE HRH3, KCNH3, BRPF3 PTGDR2 1062/4885PSEN1 2126/4885PSEN2 1867/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.